50 Transcriptomic Analysis of Plaque Psoriasis During Anti-Il-17a Biologic Therapy and Drug Withdrawal

L. Chen,L. Zhang,X. Xu,Q. Xu,F. Xue,P. Hao,X. Li,J. Zheng
DOI: https://doi.org/10.1016/j.jid.2023.09.058
IF: 7.59
2023-01-01
Journal of Investigative Dermatology
Abstract:Background: The effectiveness of IL-17A monoclonal antibody in treating chronic plaque psoriasis is well-documented; however, relapse is inevitable upon drug withdrawal. Objectives: By analyzing transcriptome profile in patients with plaque psoriasis before and after IL-17A treatment, as well as the early stage of relapse, we investigated the impact of relapse on local inflammation and comorbidities in psoriasis. Methods: We recruited 26 patients with moderate-to-severe plaque psoriasis treated with ixekizumab. After achieving a satisfactory response, the medication was discontinued. Clinical data and skin samples were collected before and after treatment (reaching> PASI75), as well as during recurrence (PGA score ≥ 3 or PASI ≥ 50% of baseline), and were performed with RNA sequencing. Results: CIBERSORT analysis revealed an increase in the proportion of resting innate immune cells after treatment. Additionally, the expression of mast cell-related genes(FCER1A, PILRA) showed a correlation with the duration of relapse, suggesting a potential involvement of mast cells in early relapse.. Following treatment, chemokines (CCL20, CCL2, CCL17, CCL19, CXCL1, CXCL2, CXCL3, CXCL10), their corresponding receptors, antimicrobial peptides (CAMPs, S100As), and inflammatory pathways (JAK/TLRs/NODs/NF-KB) were down-regulated. However, upon drug withdrawal and relapse, they rapidly up regulated and sometimes exceeded the baseline levels, indicating an inflammatory rebound in the early stage of relapse. Notably, the expression of the chemokine receptor CCR6 did not show significant changes after treatment, but higher expression of CCR6 after treatment were associated with shorter durations of relapse. The pathways associated with coronary heart disease, hypertension, and obesity showed up-regulation during relapse, compared to baseline and post-treatment conditions. Additionally, chemokines like CCR6 play a role in psoriatic co-morbidities, particularly psoriatic arthritis. Conclusion: Our findings indicate that there is an inflammatory rebound at the transcriptomic level during the early stage of relapse, highlighting the potential of mast cell-targeted treatment to sustain disease remission. Inhibiting chemokine receptors like CCR6 has the potential to prevent relapse, mitigate psoriatic metabolic co-morbidities.
What problem does this paper attempt to address?